Login to Your Account



Biosimilar pricing, delays in guidance rankle patients and providers

By Mari Serebrov
Regulatory Editor

Thursday, October 20, 2016

While the FDA and industry are gung-ho about the commitments they fine-tuned for the second rendition of the biosimilar user fee agreement (BsUFA), patient advocacy groups and health care providers aren't so happy with some of the measures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription